Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quantum BioPharmaSTU:0K91 -6.84%38 FCF Yield % is -28.46 as of Jul. 21, 2026. GuruFocus rates STU:0K91 with a GF Score™ of 38/100. The stock has 5 warning signs investors should review. Among 1,409 Biotechnology companies, Quantum BioPharma ranks worse than 72.53% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Quantum BioPharma FCF Yield % Related Terms
Quantum BioPharma FCF Yield % Historical Data
* Premium members only.
The historical data trend for Quantum BioPharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0K91 vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Quantum BioPharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quantum BioPharma FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quantum BioPharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Quantum BioPharma's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quantum BioPharma (STU:0K91) has a FCF Yield % of -28.46 as of Jul. 21, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Quantum BioPharma and its competitors. According to the industry distribution chart, Quantum BioPharma ranks #1022 out of 1409 companies in the Biotechnology industry, placing it in the top 72.5%.
Is Quantum BioPharma's FCF Yield % too high?
Quantum BioPharma's current FCF Yield % is -28.46. Based on the distribution chart, Quantum BioPharma ranks #1022 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Quantum BioPharma has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Quantum BioPharma's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Quantum BioPharma ranks #1022 out of 1409 companies for FCF Yield %. This places Quantum BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Quantum BioPharma and its competitors. Quantum BioPharma's current FCF Yield % is -28.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quantum BioPharma stock overvalued right now?
Quantum BioPharma (STU:0K91) has a current FCF Yield % of -28.46. The current FCF Yield % is -28.46. Quantum BioPharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Quantum BioPharma (STU:0K91), the current FCF Yield % is -28.46 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
38GF Score
Get the complete analysis for STU:0K91
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0K91 has been successfully added to your 
